Previous 10 | Next 10 |
Summary PL9643 is being explored in a phase 3 study treating patients with Dry Eye Disease; Results from this late-stage study are expected in Q2 of 2023. The global dry eye disease market is expected to become a $7.78 billion market by 2025. Two sets of results from phase 3 s...
Palatin Announces Presentation at the Eyecelerator@AAO 2022 Conference PR Newswire Overview of Development Pipeline of Melanocortins for Treatment of Ocular Conditions and Role in Resolving Inflammation PL9643 Phase 3 Study Results in Dry Eye Disease Currently ...
Palatin to Participate in Ladenburg Thalmann Healthcare Conference PR Newswire CRANBURY, N.J. , Sept. 29, 2022 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecu...
Palatin Technologies, Inc. (PTN) Q4 2022 Earnings Conference Call September 22, 2022, 11:00 AM ET Company Participants Carl Spana - President and CEO Stephen T. Wills - CFO, COO, and Treasurer and Secretary Conference Call Participants Joe Pantginis - H.C...
Shares of micro-cap biopharma Palatin Technologies ( NYSE: PTN ) fell as much as 10.5% to $7.1 in Thursday afternoon trading, despite the company reporting a narrower Q4 loss and a big jump in revenue. It is worth noting that PTN stock has been on a downward trend since ...
Palatin Tech press release ( NYSE: PTN ): Q4 GAAP EPS of -$1.34 misses by $0.53 . Revenue of $0.77M (+352.9% Y/Y) beats by $0.55M . Total prescriptions dispensed increased 49% over the prior quarter, increased 54% compared to the comparable quarter in 2021. ...
Palatin Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Provides Corporate Update PR Newswire Phase 3 Pivotal Study of PL9643 in Patients with Dry Eye Disease Ongoing Positive Interim Analysis – DMC Recommended Study Sample Size of 350 Patien...
Palatin Tech ( NYSE: PTN ) is scheduled to announce Q4 earnings results on Thursday, September 22nd, before market open. The consensus EPS Estimate is -$0.81 and the consensus Revenue Estimate is $0.22M (+29.4% Y/Y). Over the last 3 months, EPS estimates have seen 2 ...
Palatin to Report Fourth Quarter and Fiscal Year End 2022 Results; Teleconference and Webcast to be held on September 22, 2022 PR Newswire CRANBURY, N.J. , Sept. 19, 2022 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) will announce its fo...
The shares of commercial-stage biotech Palatin Technologies, Inc. ( NYSE: PTN ) jumped ~24% Thursday on above-average volume after the company announced the initiation of its Phase 2 clinical study for PL8177, an oral candidate for ulcerative colitis. The trial with a ...
News, Short Squeeze, Breakout and More Instantly...
Palatin Technologies Inc. Company Name:
PTN Stock Symbol:
NYSE Market:
Palatin Technologies Inc. Website:
Palatin Reports Third Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update PR Newswire Positive Phase 3 PL9643 MELODY-1 Pivotal Study Results Co-Primary Symptom Endpoint of Pain Met Statistical Significance (P<0.025) and 7 of 11 Secondary Sympt...
Palatin to Report Third Quarter Fiscal Year 2024 Results; Teleconference and Webcast to be held on May 15, 2024 PR Newswire CRANBURY, N.J. , May 9, 2024 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) will announce its third quarter fiscal year 20...
Palatin Announces FDA Clearance of IND Application for the Co-Administration of Bremelanotide with Tirzepatide (GLP-1) for the Treatment of Obesity PR Newswire Phase 2 clinical study expected to begin in mid-calendar year 2024 Topline data expected by calendar ye...